<<<<<"I have a difficult time believing that low price is an inducement not to prescribe">>>>
I never said that. What I said is that the low price should not be seen as a some kind of inducement to prescribe.
The price for drugs in serious diseases is set between the pharma/biotech and the reimbursers/insurers, on the basis of "worth" using economic/prognosis models. A novel therapy exceeding SoC gets a premium; those falling short get the opposite.
Unless you think that the low price is targeted at the segment of the population who dont have insurance coverage.
Market Data 
Markets 
AI
